Divi's Laboratories (DIVISLAB.NS) Aktie Kurs
Divi's Laboratories Kurs
De seneste 19 år voksede Divi's Laboratoriess omsætning med 18,4 % årligt og nåede 93,60 Mrd. INR. Indtjening pr. aktie er vokset med 19,8 % om året de seneste 19 år. For Divi's Laboratories er nettoavance på 23,4 % ned i forhold til 28,5 % for et par år siden. Ved dagens kurs bliver direkteafkastet cirka 0,30 %. Udlodningsandelen er omkring 36 % af indtjeningen. Udbyttet er vokset med 24,0 % om året de seneste 19 år. Konsensus 12-måneders kursmål for Divi's Laboratories er 7.012,50 INR, cirka under kursen med 30,5 %. Af 36 analytikere anbefaler 20 køb — den samlede vurdering er Køb.
Divi's Laboratories aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Divi's Laboratories aktie og aktieanalyse
Hyppigt stillede spørgsmål om Divi's Laboratories-aktien
The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.
Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.
The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.
Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.
Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.
Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.
Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 6.987,18 INR for Divi's Laboratories-aktien (median: 7.012,50 INR), svarende til -30,6 % i forhold til seneste kurs. Konsensus bygger på 36 analytikervurderinger.
36 analytikere vurderer i øjeblikket Divi's Laboratories-aktien: 21 anbefaler køb, 6 hold og 9 salg. For 2026 forventer analytikere, at Divi's Laboratories genererer omsætning på 106,46 Mrd. INR og indtjening pr. aktie på 115,11 INR.
Omregnet til den aktuelle valutakurs handles Divi's Laboratories-aktien til 95,00 EUR (10.094,00 INR).
Divi's Laboratories-aktien (DIVISLAB.NS) er noteret på 2 børser, herunder: NSE (Indien) (DIVISLAB.NS).
Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.
forventet-omsætningen for Divi's Laboratories er 106,46 Mrd. INR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Divi's Laboratories er 30,53 Mrd. INR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Divi's Laboratories er i øjeblikket 87,69. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Divi's Laboratories-aktien.
Pris-til-salgs-forholdet (P/S) for Divi's Laboratories er i øjeblikket 25,15. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Divi's Laboratories-aktien.
AlleAktien-kvalitetsscore for Divi's Laboratories er 7/10.
ISIN for Divi's Laboratories er INE361B01024. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
Tickeren for Divi's Laboratories er DIVISLAB.NS. Tickersymbolet bruges til at handle Divi's Laboratories-aktier på børsen.
Divi's Laboratories aktie
Divi's Laboratories Peer Group
Divi's Laboratories Ticker
Divi's Laboratories FIGI
Alle fundamentale data om Divi's Laboratories i deep dive
Vores aktieanalyse af Divi's Laboratories-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Divi's Laboratories. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: